EyeGate Pharma to Present at the JMP Securities 3rd Annual Healthcare Focus Conference
EyeGate Pharma, a specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics to treat serious ocular diseases, today announced that Stephen From, President and Chief Executive Officer of EyeGate Pharma, will present a corporate overview at the upcoming JMP Securities 3rd Annual Healthcare Focus Conference, taking place from October 6-7, 2008, at Le Parker Meridien Hotel in New York, NY. Mr. From's presentation will take place on October 6 at 12:30PM in the Azekka room. He will be available for one-on-one meetings with potential investors during the conference. For more information on the conference, please visit http://www. jmpsecurities. com/about/events. html.
Waltham, MA (PRWEB) October 1, 2008
EyeGate Pharma, a specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics to treat serious ocular diseases, today announced that Stephen From, President and Chief Executive Officer of EyeGate Pharma, will present a corporate overview at the upcoming JMP Securities 3rd Annual Healthcare Focus Conference, taking place from October 6-7, 2008, at Le Parker Meridien Hotel in New York, NY. Mr. From's presentation will take place on October 6 at 12:30PM in the Azekka room. He will be available for one-on-one meetings with potential investors during the conference. For more information on the conference, please visit http://www. jmpsecurities. com/about/events. html.
About EyeGate Pharma
EyeGate Pharma has recently initiated a Phase II clinical study in acute anterior uveitis designed to assess the safety and tolerability of the non-invasive EyeGate® II Ocular Drug Delivery System and plans to initiate an additional Phase II clinical trial with EGP-437 in dry eye later in 2008. EyeGate was founded in 1998 with technology licensed from Bascom Palmer Eye Institute at the
University of Miami. EyeGate's transscleral (white membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was developed to safely deliver a wide range of therapeutics to both the anterior (front) and posterior (back) chambers of the eye. The Company has recently secured $15 million in a Series C venture financing round from investors Medicis Capital, Ventech, Innoven Partenaires and The Nexus Group. The Series C funding brings the total venture investment in EyeGate to $31 million to date. For more information, please visit http://www. eyegatepharma. com.
###
